On March 7, 2024 Montdorex Inc. ("Montdorex" or "the Company"), a privately-owned precision medicine company, reported that Terry Chow, Ph.D., Founder and CEO will present insights on the relevance of inhibiting the endo-exonuclease (EE) enzyme in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in San Diego, CA, April 5-10, 2024 (Press release, Montdorex, MAR 7, 2024, View Source [SID1234640954]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The endo-exonuclease enzyme plays a key role in DNA damage repair mechanisms, but it is also overexpressed in cancer tumors. In a proof-of-concept study, Montdorex showed that tumors with increased EE expression showed the best response to pentamidine, an endo-exonuclease inhibitor. The Company has also identified mono- and di-amidine analogs of pentamidine that are more effective than the parent drug in both in vitro and in vivo studies.
"Our lead candidate, MTDX203, showed an increased anti-cancer activity with a higher safety index than pentamidine in preclinical animal studies," said Terry Chow of Montdorex. "I look forward to presenting our detailed findings to the AACR (Free AACR Whitepaper) scientific and investor community at the upcoming annual meeting."
Details of the AACR (Free AACR Whitepaper) poster presentation are as follows:
Poster Presentation (#5604): Modulating DNA repair through endo-exonuclease inhibition: a new therapeutic paradigm in Oncology [link to the abstract]
Session Category:
Molecular/Cellular Biology and Genetics
Session Title:
DNA Damage and Repair 2
Session Date and Time:
Tuesday, April 9, 2024 1:30 PM – 5:00 PM (PT)
Location:
Poster Section 14, Poster Board Number 2